ePharmaSolutions' ReferralPlus Increases Match Rate For Clinical Trial Volunteers By More than 66%
ePharmaSolutions, a provider of eClinical solutions, announced positive results of initial pilot studies for its patient matching and triaging solution, ReferralPlus.
ePharmaSolutions, a provider of eClinical solutions, announced positive results of initial pilot studies for its patient matching and triaging solution, ReferralPlus™. ReferralPlus™ was designed by ePharmaSolutions as a tool to match patients who disqualify for one study with others they might qualify for using a geo-therapeutic matching algorithm with other studies listed on their technology.
In 2012, ePharmaSolutions organized more than 30 major pharmaceutical companies and CROs to participate in the pilots to determine if they could help increase enrollment rates by triaging/matching patients who disqualified from one clinical trial to trials listed by other participating sponsors. The pilots started at the end of 2013 with the early results showing a significant improvement in cross-study matching which will offer significant economic advantages to pharmaceutical companies recruiting patients while providing patients with more opportunities to find for the right study.
The pilot data came from three pharmaceutical companies who listed their studies on the CenterWatch™ web listing service and used the ReferralPlus™ screening and matching solution. None of the pilot studies included an advertising outreach budget.
The results are summarized below:
- 33% of the total patients who screened for one study were eligible for and referred to a study site
- 18% of patients who disqualified from the first study, pre-qualified and were referred to another study
- 50% of patients who disqualified for any of the studies listed, registered to be contacted about future studies
Read the full release here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
